Key facts
- This page summarizes Nicole Murphy's Form 4 filing for BIOGEN INC. (BIIB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Feb 2026, 20:16.
Nicole Murphy - 12 Feb 2026 Form 4 Insider Report for BIOGEN INC. (BIIB)
- Reporting relationship
- Head of Pharm Ops and Tech
- Issuer ticker
- BIIB
- Reported as of
- 12 Feb 2026
- Net transaction value
- +$585
- SEC form
- 4
- Accepted by SEC
- 17 Feb 2026, 20:16:40 UTC
- Prior SEC filing
- 10 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wendell Taylor, attorney in fact for Nicole Murphy
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nicole Murphy filed Form 4 for BIOGEN INC. (BIIB) on 17 Feb 2026.
Change
- Previous filing in this sequence was filed on 10 Feb 2026.
- Current net transaction value: +$585.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001910644
Primary reporting owner
Murphy Nicole
- Relationship
- Head of Pharm Ops and Tech
- Address
- 225 BINNEY STREET, CAMBRIDGE
- Signature
- /s/ Wendell Taylor, attorney in fact for Nicole Murphy
- Signature date
- 17 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIIB
transaction
Common Stock
Purchase
- Transaction value
- $585
- Shares
- +3
- Change %
- +0.02%
- Price
- $195.04
- Shares after
- 19,611
- Date
- 12 Feb 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIIB
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +10,560
- Change %
- Price
- $0.000000
- Shares after
- 10,560
- Date
- 13 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,560
- Exercise price
- $0.000000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.